Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Ralimetinib |
Trade Name | |
Synonyms | LY2228820|LY-2228820|LY 2228820 |
Drug Descriptions |
Ralimetinib (LY2228820) is a selective ATP competitive inhibitor of p38 MAPK alpha (MAPK14) and beta (MAPK11), which inhibits tumor growth (PMID: 26581242, PMID: 24356814, PMID: 31791552, PMID: 31707688). |
DrugClasses | p38-alpha Inhibitor 1 |
CAS Registry Number | 862505-00-8 |
NCIT ID | C143046 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Carboplatin + Gemcitabine + Ralimetinib | Carboplatin Gemcitabine Ralimetinib | 0 | 0 |
Prexasertib + Ralimetinib | Prexasertib Ralimetinib | 0 | 1 |
Ralimetinib | Ralimetinib | 0 | 1 |
Ralimetinib + SCH772984 | Ralimetinib SCH772984 | 0 | 0 |